This study is exploring the drug **dupilumab** for kids with *eosinophilic esophagitis* (EoE), a condition that inflames the food pipe and affects eating. The study will last 24 weeks, aiming to see if the drug is safe, easy to handle, and works well for the children. It will also check for any potential side effects, how much of the drug is present in the blood over time, and if the body creates antibodies against it, which could affect its success or cause side effects.
- **Study Duration:** 24 weeks
- **Eligibility:** Children aged 6 months to under 15 kg with active EoE
- **Restrictions:** Can't have been in a dupilumab trial before or changed diet recently